MBX Biosciences CFO Richard Bartram resigns; John Smither named interim CFO

MBX Biosciences, Inc.

CFO Richard Bartram resigns effective March 15, 2026; will serve as consultant post-resignation.
John Smither appointed Interim CFO effective March 16, 2026; base salary $325k, target bonus 40%, $25k sign-on.
Lease entered for 13,642 sqft office/lab in Burlington, MA; aggregate base rent ~$3.4M over 4-year term.
Departure not due to dispute; search for permanent CFO underway.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MBX Biosciences, Inc. entered into Lease Agreement with 5 Burlington Woods, LLC valued at approximately $3.4 million (effective 2026-02-24).

Action: entry
Agreement: lease
Counterparty: 5 Burlington Woods, LLC
Value: approximately $3.4 million
Effective: 2026-02-24

Exact text from the filing

On February 24, 2026, MBX Biosciences, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement”) with 5 Burlington Woods, LLC ("5 Burlington Woods") to lease approximately 13,642 square feet of new office and laboratory space in Burlington, MA

View on SEC.gov

272 material agreements filed in the last 30 days. Browse all material agreements →

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-079286

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.